Loading... Please wait...

About Clotacin

Clotacin is a multivitamin without K for patients on Warfarin, Coumadin, Jantoven and other blood thinners.   Clotacin is specially formulated not to affect patients INR’s.

Clotacin is the second multivitamin developed for people on blood thinners.  The first multivitamin developed for people on blood thinners was Clotamin, which we founded and brought to market in 2008.  We are no longer affiliated with Clotamin, in an attempt to bring Clotamin to a bigger audience we partnered with a larger healthcare company that would allow Clotamin to roll out into the larger chain drug stores.   In an attempt to grow we lost focus on why we started Clotamin in the first place, which was to provide a quality multivitamin formulated for the special needs of those taking blood thinners.   So we are excited to get back to focusing on you the customer and provide you the best in customer service as well as the highest quality multivitamin without K produced right here in the USA.  Clotacin is manufactured in a GMP certified laboratory which is the gold standard in nutritional supplement manufacturing.  If you compare our formulation to that of Clotamin you will see that they are identical except for the fact we doubled the amount of vitamin B12 to provide you extra energy.

For those of you that just recently went on blood thinners and are looking for a vitamin without K for the first time you have come to the right place.  As a result of having factor V ledien thrombophilia I suffered a pulmonary embolism in 2006.  I began warfarin then and will be on it for the rest of my life.  We know firsthand the challenges of life on warfarin. Clotacin is a complete multivitamin that will not affect your INR.  Clotacin was developed by warfarin patients for warfarin patients.

Thank you for checking out our website.  To receive special offers please sign up to receive our newsletter or like us on Facebook or follow us on Twitter.

 

Kindest Regards,

Justin and Kelly Barch

image1.jpg



Categories

Newsletter